Protein Design Labs Inc. (PDL) of Mountain View, Calif.,reported Tuesday that two of its humanized anti-herpesantibodies reduced mortality in infected mice by up to 90percent, depending on the dose and the time between infectionand treatment. The mice were infected with the herpes simplexviruses type 1 and type 2.

The results were reported by University of Alabama,Birmingham, School of Medicine virologist Earl R. Kern at theIBC International Conference on Antibody Engineering in SanDiego. PDL plans to begin clinical trials using one of its anti-herpes antibodies for an initial indication of neonatal herpes inthe second half of 1993. PDL (NASDAQ:PDLI) closed Tuesday at$11.88, down 25 cents a share.

(c) 1997 American Health Consultants. All rights reserved.